<?xml version="1.0" encoding="UTF-8"?>
<ref id="R6">
 <label>6</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <string-name>
    <surname>Davis</surname>
    <given-names>ID</given-names>
   </string-name>, 
   <string-name>
    <surname>Martin</surname>
    <given-names>AJ</given-names>
   </string-name>, 
   <string-name>
    <surname>Stockler</surname>
    <given-names>MR</given-names>
   </string-name>, 
   <etal>et al</etal>
  </person-group>. 
  <article-title>Enzalutamide with standard first-line therapy in metastatic prostate cancer</article-title>. 
  <source>N Engl J Med</source>
  <year>2019</year>;
  <volume>381</volume>:
  <fpage>121</fpage>â€“
  <lpage>31</lpage>. 
  <pub-id pub-id-type="doi">10.1056/NEJMoa1903835</pub-id>
  <?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/31157964?>
  <pub-id pub-id-type="pmid">31157964</pub-id>
 </mixed-citation>
</ref>
